Screener / SEC EDGAR /CIK 0001520262 /10-K filed Feb 25, 2026, compared with Feb 12, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Alkermes plc. ALKS

Compare with peers Embed
Earnings releases

Latest results release: Nov 3, 2026

8-K item 2.02, exhibit 99

What ALKS's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

What the company says its adjusted numbers leave out:

Non-GAAP net income adjusts for certain one-time and non-cash charges by excluding from GAAP results: share-based compensation expense; amortization; depreciation; non-cash net interest expense; change in the fair value of contingent consideration; certain other one-time or non-cash items; and the income tax effect of these reconciling items. release Feb 12, 2025

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 3, 2026 · EX-99.1

Alkermes plc Reports Third Quarter 2026 Financial Results — Third Quarter

Open on SEC

Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927

Alkermes plc Reports Third Quarter 2026 Financial Results — Third Quarter Revenues of $480.1 Million — — GAAP Net Income of $16.3 Million and Adjusted EBITDA of $120.1 Million — — Company Reiterates 2026 Financial Expectations — DUBLIN, Nov. 3, 2026 — Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2026. “We delivered solid commercial and financial performance in the third quarter while continuing to advance our portfolio of orexin 2 receptor agonists in central disorders of hypersomnolence and other neuropsychiatric conditions,” said Blair Jackson, President and Chief Executive Officer of Alkermes. “The rapid expansion of our orexin development programs, highlighted by our recent clinical proof-of-concept data in ADHD and initiation of a phase 2 study in major depressive disorder, further strengthens our leadership position in orexin-based research. As we continue to advance our orexin development portfolio, we are growing the body of evidence supporting the potential of orexin biology across multiple neuropsychiatric disorders and expect several important clinical data readouts over the year ahead. With a portfolio of development candidates in one of the most exciting new therapeutic categories in neuroscience and a steady cadence of clinical data readouts ahead, we believe we are well positioned to drive long-term value for shareholders.” Key Financial Highlights Revenues

Revenue Highlights Proprietary Product Revenues • VIVITROL revenues for the quarter were $127.6 million. During the quarter, the company recorded VIVITROL revenue of approximately $8 million related to gross-to-net favorability, primarily driven by favorable patient mix. 1 • ARISTADA i revenues for the quarter were $103.9 million, which included approximately $4 million of inventory benefit related to timing of shipments. During the quarter, the company recorded ARISTADA revenue of approximately $3 million related to gross-to-net favorability, primarily driven by favorable patient mix. • LYBALVI revenues for the quarter were $95.9 million, which included approximately $2 million of inventory benefit related to timing of shipments. Total prescriptions grew 18% compared to the third quarter of 2025. • LUMRYZ revenues for the quarter were $89.9 million. At the end of the third quarter, approximately 4,100 patients were on LUMRYZ therapy. Manufacturing & Royalty Revenues • VUMERITY ® manufacturing and royalty revenues for the quarter were $29.5 million. • Royalty revenue from XEPLION ® , INVEGA TRINZA ® /TREVICTA ® and INVEGA HAFYERA ® /BYANNLI ® for the quarter were $26.4 million. Key Operating Expenses

(1) Includes $20.2 million of share-based compensation expense related to the acceleration of vesting of equity awards for former Avadel Pharmaceuticals plc (Avadel) employees which vested in full upon the closing of the transaction. Balance Sheet • At Sept. 30, 2026, the company recorded cash, cash equivalents and total investments of $787.6 million, compared to $691.6 million at June 30, 2026. Financial Expectations for 2026 Alkermes reiterates its financial expectations for 2026, as set forth in its press release dated July 28, 2026. Conference Call Alkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026, to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes’ website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes’ website. 2 About Alkermes plc

Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes has established a leadership position in orexin biology and is advancing a portfolio of investigational orexin 2 receptor agonists for narcolepsy, idiopathic hypersomnia and other psychiatric and neurological disorders, including attention-deficit hyperactivity disorder (ADHD), major depressive disorder (MDD) and fatigue associated with multiple sclerosis and Parkinson’s disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

This press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the U.S. (GAAP), including EBITDA and Adjusted EBITDA. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.

EBITDA represents earnings before interest, tax, depreciation and amortization. Adjusted EBITDA excludes share-based compensation expense and non-recurring gains or losses in addition to the components of EBITDA from earnings.

The company’s management and board of directors utilize these non-GAAP financial measures to evaluate the company’s performance. The company provides these non- GAAP financial measures of the company’s performance to investors because management believes that these non-GAAP financial measures, when viewed with the company’s results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, EBITDA and Adjusted EBITDA are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, EBITDA and Adjusted EBITDA should not be considered measures of the company’s liquidity.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release.

Certain statements set forth in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company’s expectations concerning its future financial and operating performance, business plans or prospects, including expectations related to value creation; and expectations regarding development timelines for, and the potential therapeutic and commercial value of, the company’s orexin development candidates. The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the company may not be able to achieve its financial expectations, including those related to value creation; clinical development activities may not be completed on time or at all; clinical study results may not be predictive of results from future stages of ongoing clinical studies, future clinical studies or real-world results; the unfavorable outcome of arbitration, litigation, or other proceedings or disputes related to the company’s products or products using the company’s proprietary technologies; the company’s products or product candidates may be shown to be ineffective or unsafe; the U.S. Food and Drug Administration or regulatory authorities outside the U.S. may not agree with the company’s regulatory approval strategies or components of its development programs, including clinical trial designs, conduct and methodologies, and may make adverse decisions regarding the company’s products; the company and its licensees may not be able to 3 continue to successfully commercialize their products or support revenue growth from such products; potential changes in the competitive landscape impacting our products, including earlier than anticipated entry of competition from generic forms of our products or competitive products and negotiated maximum fair pricing of competitive products; potential changes in the cost, scope and duration of the company’s development programs; there may be a reduction in payment rate or reimbursement for the company’s products or an increase in the company’s financial obligations to government payers; the company’s products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended Dec. 31, 2025 and in subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC’s website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release. VIVITROL ® is a registered trademark of Alkermes, Inc.; ARISTADA ® , ARISTADA INITIO ® and LYBALVI ® are registered trademarks of Alkermes Pharma Ireland Limited, used by Alkermes, Inc. under license; LUMRYZ ® is a registered trademark of Flamel Ireland Limited, an affiliate of Alkermes plc; BYANNLI ® , INVEGA HAFYERA ® , INVEGA TRINZA ® , TREVICTA ® and XEPLION ® , are registered trademarks of Johnson & Johnson or its affiliated companies; and VUMERITY ® is a registered trademark of Biogen MA Inc., used by Alkermes under license. (tables follow)

i The term “ARISTADA” as used in this press release refers to ARISTADA and ARISTADA INITIO®, unless the context indicates otherwise.

Alkermes plc and Subsidiaries Selected Financial Information (Unaudited) Condensed Consolidated Statements of Operations - GAAP (In thousands, Three Months Three Months except per Ended Ended share data) September 30, September 30, Revenues: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Product sales, $ 417,280 $ 317,423 net Manufacturing and royalty 62,852 76,762 revenues Total Revenues 480,132 394,185 Expenses: Cost of goods manufactured 94,220 51,591 and sold Research and 121,120 81,739 development Selling, general and 208,502 171,773 administrative Amortization of acquired 19,698 — intangible assets Change in the fair value of 568 — contingent consideration Total Expenses 444,108 305,103 Operating 36,024 89,082 Income Other (Expense) Income, net: Interest 6,487 11,943 income Interest (27,551 ) — expense Other expense, (223 ) (280 ) net Total Other (Expense) (21,287 ) 11,663 Income, net Income Before 14,737 100,745 Income Taxes Income Tax (Benefit) (1,550 ) 17,984 Provision Net Income — $ 16,287 $ 82,761 GAAP Earnings Per $ 0.10 $ 0.50 Share - Basic Earnings Per Share - $ 0.09 $ 0.49 Diluted Weighted Average Number of Ordinary Shares Outstanding: Basic 167,872 165,086 Diluted 176,370 168,510 An itemized reconciliation between net income on a GAAP basis and Adjusted EBITDA is as follows: Net Income — $ 16,287 $ 82,761 GAAP Adjustments: Interest (6,487 ) (11,943 ) income Interest 27,551 — expense Income tax (benefit) (1,550 ) 17,984 provision Depreciation 7,461 8,060 expense Amortization of acquired 19,698 19 intangible assets EBITDA 62,960 96,881 Share-based 26,747 24,665 compensation Costs related to the 29,790 — acquisition of Avadel Change in the fair value of 568 — contingent consideration Adjusted $ 120,065 $ 121,546 EBITDA

Alkermes plc and Subsidiaries Selected Financial Information (Unaudited) Condensed Consolidated Statements of Operations - GAAP (In thousands, Nine Months Nine Months except per Ended Ended share data) September 30, September 30, Revenues: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Product $ 1,167,118 $ 869,151 sales, net Manufacturing and royalty 201,934 222,201 revenues Total 1,369,052 1,091,352 Revenues Expenses: Cost of goods manufactured 253,910 150,248 and sold Research and 337,385 230,926 development Selling, general and 690,720 514,326 administrati… Amortization of acquired 53,958 — intangible assets Change in the fair value of 26,982 — contingent consideration Total 1,362,955 895,500 Expenses Operating 6,097 195,852 Income Other (Expense) Income, net: Interest 20,370 33,174 income Interest (74,368 ) — expense Other (expense) (1,164 ) 2,047 income, net Total Other (Expense) (55,162 ) 35,221 Income, net (Loss) Income Before Income (49,065 ) 231,073 Taxes Income Tax 627 38,750 Provision Net (Loss) $ (49,692 ) $ 192,323 Income — GAAP (Loss) Earnings Per $ (0.30 ) $ 1.17 Share - Basic (Loss) Earnings Per $ (0.30 ) $ 1.14 Share - Diluted Weighted Average Number of Ordinary Shares Outstanding: Basic 167,037 164,490 Diluted 167,037 168,445 An itemized reconciliati… between net (loss) income on a GAAP basis and Adjusted EBITDA is as follows: Net (Loss) $ (49,692 ) $ 192,323 Income — GAAP Adjustments: Interest (20,370 ) (33,174 ) income Interest 74,368 — expense Income tax 627 38,750 provision Depreciation 22,907 23,262 expense Amortization of acquired 53,958 56 intangible assets EBITDA 81,798 221,217 Share-based 112,624 72,441 compensation Costs related to the acquisition 118,140 — of Avadel Change in the fair value of 26,982 — contingent consideration Adjusted $ 339,544 $ 293,658 EBITDA

Alkermes plc and Subsidiaries Selected Financial Information (Unaudited) Condensed Consolidated Balance September 30, December 31, Sheets (In thousands) 2026 2025 Cash, cash equivalents and total $ 787,574 $ 588,360 investments Restricted cash — 731,206 Receivables 459,090 334,025 Inventory 261,098 196,625 Prepaid expenses and other current 105,086 79,090 assets Property, plant and 215,023 221,722 equipment, net Intangible assets, 1,741,758 815 net Goodwill 592,519 83,027 Deferred tax assets 120,771 125,815 Other assets 152,604 126,308 Total Assets $ 4,435,523 $ 2,486,993 Accrued sales discounts, allowances $ 323,406 $ 247,126 and reserves Long-term debt, 26,500 — current portion Other current 302,027 296,311 liabilities Long-term debt 1,471,231 — Other long-term 447,638 124,261 liabilities Total shareholders' 1,864,721 1,819,295 equity Total Liabilities and Shareholders' $ 4,435,523 $ 2,486,993 Equity Ordinary shares outstanding (in 168,030 165,607 thousands) This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alkermes plc's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, which the company intends to file in November 2026.

Full text with the tables
                                                                    Exhibit 99.1
                                                             
  Alkermes Contacts:                                         
  For Investors:      Sandy Coombs     +1 781 609 6377       
  For Media:          Katie Joyce           +1 781 249 8927  
                                                             
Alkermes plc Reports Third Quarter 2026 Financial Results — Third Quarter
Revenues of $480.1 Million — — GAAP Net Income of $16.3 Million and Adjusted
EBITDA of $120.1 Million — — Company Reiterates 2026 Financial Expectations —
DUBLIN, Nov. 3, 2026 — Alkermes plc (Nasdaq: ALKS) today reported financial
results for the third quarter of 2026. “We delivered solid commercial and
financial performance in the third quarter while continuing to advance our
portfolio of orexin 2 receptor agonists in central disorders of hypersomnolence
and other neuropsychiatric conditions,” said Blair Jackson, President and Chief
Executive Officer of Alkermes. “The rapid expansion of our orexin development
programs, highlighted by our recent clinical proof-of-concept data in ADHD and
initiation of a phase 2 study in major depressive disorder, further strengthens
our leadership position in orexin-based research. As we continue to advance our
orexin development portfolio, we are growing the body of evidence supporting the
potential of orexin biology across multiple neuropsychiatric disorders and
expect several important clinical data readouts over the year ahead. With a
portfolio of development candidates in one of the most exciting new therapeutic
categories in neuroscience and a steady cadence of clinical data readouts ahead,
we believe we are well positioned to drive long-term value for shareholders.”
Key Financial Highlights Revenues
                                                                                
                         Three                             Nine                 
                        Months                           Months                 
                         Ended                            Ended                 
  (In                September                        September                 
  millions)  2026          30,  2025           2026         30,  2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Total      $           480.1  $     394.2    $        1,369.1  $     1,091.4  
  Revenues                                                                      
  Total                                                                         
  Propriet…  $           417.3  $     317.4    $        1,167.1  $       869.2  
  Net Sales                                                                     
  VIVITROL®  $           127.6  $     121.1    $          364.4  $       343.8  
  ARISTADA…  $           103.9  $      98.1    $          294.4  $       272.8  
  LYBALVI®   $            95.9  $      98.2    $          282.2  $       252.6  
  LUMRYZ®    $            89.9  $         —    $          226.0  $           —  
                                                                                
Profitability
                                                                                
                          Three                                                 
                         Months                       Nine Months               
                          Ended                             Ended               
  (In                 September                         September               
  millions)   2026          30,  2025           2026          30,  2025         
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP Net                                                                      
  Income      $            16.3  $      82.8    $           -49.7  $     192.3  
  (Loss)                                                                        
  EBITDA      $            63.0  $      96.9    $            81.8  $     221.2  
  Adjusted    $           120.1  $     121.5    $           339.5  $     293.7  
  EBITDA                                                                        
                                                                                
Revenue Highlights Proprietary Product Revenues • VIVITROL revenues for the
quarter were $127.6 million. During the quarter, the company recorded VIVITROL
revenue of approximately $8 million related to gross-to-net favorability,
primarily driven by favorable patient mix.
                                       1                                        
• ARISTADA i revenues for the quarter were $103.9 million, which included
approximately $4 million of inventory benefit related to timing of shipments.
During the quarter, the company recorded ARISTADA revenue of approximately $3
million related to gross-to-net favorability, primarily driven by favorable
patient mix. • LYBALVI revenues for the quarter were $95.9 million, which
included approximately $2 million of inventory benefit related to timing of
shipments. Total prescriptions grew 18% compared to the third quarter of 2025. •
LUMRYZ revenues for the quarter were $89.9 million. At the end of the third
quarter, approximately 4,100 patients were on LUMRYZ therapy. Manufacturing &
Royalty Revenues • VUMERITY ® manufacturing and royalty revenues for the quarter
were $29.5 million. • Royalty revenue from XEPLION ® , INVEGA TRINZA ® /TREVICTA
® and INVEGA HAFYERA ® /BYANNLI ® for the quarter were $26.4 million. Key
Operating Expenses
                                                                                
           Three                                                                
           Months                                                               
           Ended                                                                
           September         2026                                               
  (In      30,               Transac…                          2025             
  millio…  2026GAAP          Adjustm…        2026Non-…         GAAP             
 ────────────────────────────────────────────────────────────────────────────── 
  Cost of                                                                       
  Goods    $           94.2  $         28.7  $           65.6  $          51.6  
  Sold                                                                          
  R&D      $          121.1  $          0.1  $          121.0  $          81.7  
  Expense                                                                       
  SG&A     $          208.5  $          1.0  $          207.5  $         171.8  
  Expense                                                                       
                                                                                
                                                                                
           Nine                                                                 
           Months                                                               
           Ended                                                                
           September         2026                                               
  (In      30,               Transac…                          2025             
  millio…  2026GAAP          Adjustm…        2026Non-…         GAAP             
 ────────────────────────────────────────────────────────────────────────────── 
  Cost of                                                                       
  Goods    $          253.9  $         72.4  $          181.5  $         150.2  
  Sold                                                                          
  R&D      $          337.4  $          8.3  $          329.1  $         230.9  
  Expense                                                                       
  SG&A     $          690.7  $         57.6  $          633.1  $         514.3  
  Expense                                                                       
                                                                                
(1) Includes $20.2 million of share-based compensation expense related to the
acceleration of vesting of equity awards for former Avadel Pharmaceuticals plc
(Avadel) employees which vested in full upon the closing of the transaction.
Balance Sheet • At Sept. 30, 2026, the company recorded cash, cash equivalents
and total investments of $787.6 million, compared to $691.6 million at June 30,
2026. Financial Expectations for 2026 Alkermes reiterates its financial
expectations for 2026, as set forth in its press release dated July 28, 2026.
Conference Call Alkermes will host a conference call and webcast presentation
with accompanying slides at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3,
2026, to discuss these financial results and provide an update on the company.
The webcast may be accessed on the Investors section of Alkermes’ website at
www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988
for U.S. callers and +1 201 389 0923 for international callers. In addition, a
replay of the conference call may be accessed by visiting Alkermes’ website.
                                       2                                        
About Alkermes plc                                                              
                                                                                
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global     
biopharmaceutical company that seeks to develop innovative medicines in the     
field of neuroscience. The company has a portfolio of proprietary commercial    
products for the treatment of alcohol dependence, opioid dependence,            
schizophrenia, bipolar I disorder and narcolepsy. Alkermes has established a    
leadership position in orexin biology and is advancing a portfolio of           
investigational orexin 2 receptor agonists for narcolepsy, idiopathic           
hypersomnia and other psychiatric and neurological disorders, including         
attention-deficit hyperactivity disorder (ADHD), major depressive disorder (MDD)
and fatigue associated with multiple sclerosis and Parkinson’s disease.         
Headquartered in Ireland, Alkermes also has a corporate office and research and 
development center in Massachusetts and a manufacturing facility in Ohio. For   
more information, please visit Alkermes’ website at www.alkermes.com.           
                                                                                
Non-GAAP Financial Measures                                                     
                                                                                
This press release includes information about certain financial measures that   
are not prepared in accordance with generally accepted accounting principles in 
the U.S. (GAAP), including EBITDA and Adjusted EBITDA. These non-GAAP measures  
are not based on any standardized methodology prescribed by GAAP and are not    
necessarily comparable to similar measures presented by other companies.        
                                                                                
EBITDA represents earnings before interest, tax, depreciation and amortization. 
Adjusted EBITDA excludes share-based compensation expense and non-recurring     
gains or losses in addition to the components of EBITDA from earnings.          
                                                                                
The company’s management and board of directors utilize these non-GAAP financial
measures to evaluate the company’s performance. The company provides these non- 
GAAP financial measures of the company’s performance to investors because       
management believes that these non-GAAP financial measures, when viewed with the
company’s results under GAAP and the accompanying reconciliations, are useful in
identifying underlying trends in ongoing operations. However, EBITDA and        
Adjusted EBITDA are not measures of financial performance under GAAP and,       
accordingly, should not be considered as alternatives to GAAP measures as       
indicators of operating performance. Further, EBITDA and Adjusted EBITDA should 
not be considered measures of the company’s liquidity.                          
                                                                                
A reconciliation of GAAP to non-GAAP financial measures has been provided in the
tables included in this press release.                                          
                                                                                
Note Regarding Forward-Looking Statements                                       
                                                                                
Certain statements set forth in this press release constitute “forward-looking  
statements” within the meaning of the Private Securities Litigation Reform Act  
of 1995, as amended, including, but not limited to, statements concerning: the  
company’s expectations concerning its future financial and operating            
performance, business plans or prospects, including expectations related to     
value creation; and expectations regarding development timelines for, and the   
potential therapeutic and commercial value of, the company’s orexin development 
candidates. The company cautions that forward-looking statements are inherently 
uncertain. The forward-looking statements are neither promises nor guarantees   
and they are necessarily subject to a high degree of uncertainty and risk.      
Actual performance and results may differ materially from those expressed or    
implied in the forward-looking statements due to various risks and              
uncertainties. These risks and uncertainties include, among others: the company 
may not be able to achieve its financial expectations, including those related  
to value creation; clinical development activities may not be completed on time 
or at all; clinical study results may not be predictive of results from future  
stages of ongoing clinical studies, future clinical studies or real-world       
results; the unfavorable outcome of arbitration, litigation, or other           
proceedings or disputes related to the company’s products or products using the 
company’s proprietary technologies; the company’s products or product candidates
may be shown to be ineffective or unsafe; the U.S. Food and Drug Administration 
or regulatory authorities outside the U.S. may not agree with the company’s     
regulatory approval strategies or components of its development programs,       
including clinical trial designs, conduct and methodologies, and may make       
adverse decisions regarding the company’s products; the company and its         
licensees may not be able to                                                    
                                       3                                        
continue to successfully commercialize their products or support revenue growth
from such products; potential changes in the competitive landscape impacting our
products, including earlier than anticipated entry of competition from generic
forms of our products or competitive products and negotiated maximum fair
pricing of competitive products; potential changes in the cost, scope and
duration of the company’s development programs; there may be a reduction in
payment rate or reimbursement for the company’s products or an increase in the
company’s financial obligations to government payers; the company’s products may
prove difficult to manufacture, be precluded from commercialization by the
proprietary rights of third parties, or have unintended side effects, adverse
reactions or incidents of misuse; and those risks and uncertainties described
under the heading “Risk Factors” in the company’s Annual Report on Form 10-K for
the year ended Dec. 31, 2025 and in subsequent filings made by the company with
the U.S. Securities and Exchange Commission (SEC), which are available on the
SEC’s website at www.sec.gov. Existing and prospective investors are cautioned
not to place undue reliance on these forward-looking statements, which speak
only as of the date hereof. Except as required by law, the company disclaims any
intention or responsibility for updating or revising any forward-looking
statements contained in this press release. VIVITROL ® is a registered trademark
of Alkermes, Inc.; ARISTADA ® , ARISTADA INITIO ® and LYBALVI ® are registered
trademarks of Alkermes Pharma Ireland Limited, used by Alkermes, Inc. under
license; LUMRYZ ® is a registered trademark of Flamel Ireland Limited, an
affiliate of Alkermes plc; BYANNLI ® , INVEGA HAFYERA ® , INVEGA TRINZA ® ,
TREVICTA ® and XEPLION ® , are registered trademarks of Johnson & Johnson or its
affiliated companies; and VUMERITY ® is a registered trademark of Biogen MA
Inc., used by Alkermes under license. (tables follow)
                                                                                
  i  The term “ARISTADA” as used in this press release refers to ARISTADA and   
     ARISTADA INITIO®, unless the context indicates otherwise.                  
                                                                                
                                       4                                        
                                                                                
  Alkermes plc                                                                  
  and                                                                           
  Subsidiaries                                                                  
  Selected                                                                      
  Financial                                                                     
  Information                                                                   
  (Unaudited)                                                                   
  Condensed                                                                     
  Consolidated                                                                  
  Statements of                                                                 
  Operations -                                                                  
  GAAP                                                                          
  (In thousands,    Three Months                   Three Months                 
  except per        Ended                          Ended                        
  share data)       September 30,                  September 30,                
  Revenues:         2026                           2025                         
 ────────────────────────────────────────────────────────────────────────────── 
  Product sales,    $                417,280       $                317,423     
  net                                                                           
  Manufacturing                                                                 
  and royalty                         62,852                         76,762     
  revenues                                                                      
  Total Revenues                     480,132                        394,185     
  Expenses:                                                                     
  Cost of goods                                                                 
  manufactured                        94,220                         51,591     
  and sold                                                                      
  Research and                       121,120                         81,739     
  development                                                                   
  Selling,                                                                      
  general and                        208,502                        171,773     
  administrative                                                                
  Amortization                                                                  
  of acquired                         19,698                              —     
  intangible                                                                    
  assets                                                                        
  Change in the                                                                 
  fair value of                          568                              —     
  contingent                                                                    
  consideration                                                                 
  Total Expenses                     444,108                        305,103     
  Operating                           36,024                         89,082     
  Income                                                                        
  Other                                                                         
  (Expense)                                                                     
  Income, net:                                                                  
  Interest                             6,487                         11,943     
  income                                                                        
  Interest                           (27,551  )                           —     
  expense                                                                       
  Other expense,                        (223  )                        (280  )  
  net                                                                           
  Total Other                                                                   
  (Expense)                          (21,287  )                      11,663     
  Income, net                                                                   
  Income Before                       14,737                        100,745     
  Income Taxes                                                                  
  Income Tax                                                                    
  (Benefit)                           (1,550  )                      17,984     
  Provision                                                                     
  Net Income —      $                 16,287       $                 82,761     
  GAAP                                                                          
  Earnings Per      $                   0.10       $                   0.50     
  Share - Basic                                                                 
  Earnings Per                                                                  
  Share -           $                   0.09       $                   0.49     
  Diluted                                                                       
  Weighted                                                                      
  Average Number                                                                
  of Ordinary                                                                   
  Shares                                                                        
  Outstanding:                                                                  
  Basic                              167,872                        165,086     
  Diluted                            176,370                        168,510     
  An itemized                                                                   
  reconciliation                                                                
  between net                                                                   
  income on a                                                                   
  GAAP basis and                                                                
  Adjusted                                                                      
  EBITDA is as                                                                  
  follows:                                                                      
  Net Income —      $                 16,287       $                 82,761     
  GAAP                                                                          
  Adjustments:                                                                  
  Interest                            (6,487  )                     (11,943  )  
  income                                                                        
  Interest                            27,551                              —     
  expense                                                                       
  Income tax                                                                    
  (benefit)                           (1,550  )                      17,984     
  provision                                                                     
  Depreciation                         7,461                          8,060     
  expense                                                                       
  Amortization                                                                  
  of acquired                         19,698                             19     
  intangible                                                                    
  assets                                                                        
  EBITDA                              62,960                         96,881     
  Share-based                         26,747                         24,665     
  compensation                                                                  
  Costs related                                                                 
  to the                              29,790                              —     
  acquisition of                                                                
  Avadel                                                                        
  Change in the                                                                 
  fair value of                          568                              —     
  contingent                                                                    
  consideration                                                                 
  Adjusted          $                120,065       $                121,546     
  EBITDA                                                                        
                                                                                
                                       5                                        
                                                                                
  Alkermes plc                                                                  
  and                                                                           
  Subsidiaries                                                                  
  Selected                                                                      
  Financial                                                                     
  Information                                                                   
  (Unaudited)                                                                   
  Condensed                                                                     
  Consolidated                                                                  
  Statements of                                                                 
  Operations -                                                                  
  GAAP                                                                          
  (In                                                                           
  thousands,       Nine Months                     Nine Months                  
  except per       Ended                           Ended                        
  share data)      September 30,                   September 30,                
  Revenues:        2026                            2025                         
 ────────────────────────────────────────────────────────────────────────────── 
  Product          $               1,167,118       $                869,151     
  sales, net                                                                    
  Manufacturing                                                                 
  and royalty                        201,934                        222,201     
  revenues                                                                      
  Total                            1,369,052                      1,091,352     
  Revenues                                                                      
  Expenses:                                                                     
  Cost of goods                                                                 
  manufactured                       253,910                        150,248     
  and sold                                                                      
  Research and                       337,385                        230,926     
  development                                                                   
  Selling,                                                                      
  general and                        690,720                        514,326     
  administrati…                                                                 
  Amortization                                                                  
  of acquired                         53,958                              —     
  intangible                                                                    
  assets                                                                        
  Change in the                                                                 
  fair value of                       26,982                              —     
  contingent                                                                    
  consideration                                                                 
  Total                            1,362,955                        895,500     
  Expenses                                                                      
  Operating                            6,097                        195,852     
  Income                                                                        
  Other                                                                         
  (Expense)                                                                     
  Income, net:                                                                  
  Interest                            20,370                         33,174     
  income                                                                        
  Interest                           (74,368  )                           —     
  expense                                                                       
  Other                                                                         
  (expense)                           (1,164  )                       2,047     
  income, net                                                                   
  Total Other                                                                   
  (Expense)                          (55,162  )                      35,221     
  Income, net                                                                   
  (Loss) Income                                                                 
  Before Income                      (49,065  )                     231,073     
  Taxes                                                                         
  Income Tax                             627                         38,750     
  Provision                                                                     
  Net (Loss)       $                 (49,692  )    $                192,323     
  Income — GAAP                                                                 
  (Loss)                                                                        
  Earnings Per     $                   (0.30  )    $                   1.17     
  Share - Basic                                                                 
  (Loss)                                                                        
  Earnings Per     $                   (0.30  )    $                   1.14     
  Share -                                                                       
  Diluted                                                                       
  Weighted                                                                      
  Average                                                                       
  Number of                                                                     
  Ordinary                                                                      
  Shares                                                                        
  Outstanding:                                                                  
  Basic                              167,037                        164,490     
  Diluted                            167,037                        168,445     
  An itemized                                                                   
  reconciliati…                                                                 
  between net                                                                   
  (loss) income                                                                 
  on a GAAP                                                                     
  basis and                                                                     
  Adjusted                                                                      
  EBITDA is as                                                                  
  follows:                                                                      
  Net (Loss)       $                 (49,692  )    $                192,323     
  Income — GAAP                                                                 
  Adjustments:                                                                  
  Interest                           (20,370  )                     (33,174  )  
  income                                                                        
  Interest                            74,368                              —     
  expense                                                                       
  Income tax                             627                         38,750     
  provision                                                                     
  Depreciation                        22,907                         23,262     
  expense                                                                       
  Amortization                                                                  
  of acquired                         53,958                             56     
  intangible                                                                    
  assets                                                                        
  EBITDA                              81,798                        221,217     
  Share-based                        112,624                         72,441     
  compensation                                                                  
  Costs related                                                                 
  to the                                                                        
  acquisition                        118,140                              —     
  of                                                                            
  Avadel                                                                        
  Change in the                                                                 
  fair value of                       26,982                              —     
  contingent                                                                    
  consideration                                                                 
  Adjusted         $                 339,544       $                293,658     
  EBITDA                                                                        
                                                                                
                                       6                                        
                                                                                
  Alkermes plc and                                                              
  Subsidiaries                                                                  
  Selected Financial                                                            
  Information                                                                   
  (Unaudited)                                                                   
  Condensed                                                                     
  Consolidated Balance     September 30,               December 31,             
  Sheets                                                                        
  (In thousands)                    2026                       2025             
  Cash, cash                                                                    
  equivalents and total                $    787,574               $    588,360  
  investments                                                                   
  Restricted cash                                 —                    731,206  
  Receivables                               459,090                    334,025  
  Inventory                                 261,098                    196,625  
  Prepaid expenses and                                                          
  other current                             105,086                     79,090  
  assets                                                                        
  Property, plant and                       215,023                    221,722  
  equipment, net                                                                
  Intangible assets,                      1,741,758                        815  
  net                                                                           
  Goodwill                                  592,519                     83,027  
  Deferred tax assets                       120,771                    125,815  
  Other assets                              152,604                    126,308  
  Total Assets                         $  4,435,523               $  2,486,993  
  Accrued sales                                                                 
  discounts, allowances                $    323,406               $    247,126  
  and                                                                           
  reserves                                                                      
  Long-term debt,                            26,500                          —  
  current portion                                                               
  Other current                             302,027                    296,311  
  liabilities                                                                   
  Long-term debt                          1,471,231                          —  
  Other long-term                           447,638                    124,261  
  liabilities                                                                   
  Total shareholders'                     1,864,721                  1,819,295  
  equity                                                                        
  Total Liabilities and                                                         
  Shareholders'                        $  4,435,523               $  2,486,993  
  Equity                                                                        
  Ordinary shares                                                               
  outstanding (in                           168,030                    165,607  
  thousands)                                                                    
  This selected                                                                 
  financial information                                                         
  should be read in                                                             
  conjunction with the                                                          
  consolidated                                                                  
  financial statements                                                          
  and                                                                           
  notes thereto                                                                 
  included in Alkermes                                                          
  plc's                                                                         
  Quarterly Report on                                                           
  Form 10-Q for the                                                             
  quarter ended                                                                 
  September 30, 2026,                                                           
  which                                                                         
  the company intends                                                           
  to file in November                                                           
  2026.                                                                         
                                                                                
                                       7                                        
                                                                                
  Alke…                                                                         
  plc                                                                           
  and                                                                           
  Subs…                                                                         
  Summ…                                                                         
  of                                                                            
  Costs                                                                         
  Rela…    Three                                                                
  to       Months                              Net of                           
  the      Ended             Costs             Costs             Three          
  Acqu…    Septe…            Relat…            Relat…            Months         
  of       30,               to the            to the            Ended          
  Avad…    2026              Acqui…            Acqui…            Septe…         
  (In      GAAP              of                of                30,            
  thou…    Resul…            Avadel            Avadel            2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Cost                                                                          
  of                                                                            
  goods    $       94,220    $       28,650    $       65,570    $       51,5…  
  manu…                                                                         
  and                                                                           
  sold                                                                          
  Rese…                                                                         
  and      $       121,1…    $          111    $       121,0…    $       81,7…  
  deve…                                                                         
  Sell…                                                                         
  gene…    $       208,5…    $        1,029    $       207,4…    $       171,…  
  and                                                                           
  admi…                                                                         
           Nine                                                                 
           Months                                                               
           Ended                                                                
           Septe…                                                               
           30,                                                                  
           2026                                                                 
                             Costs             Net of            Nine           
                             Relat…            Costs             Months         
  (In      GAAP              to the            Relat…            Ended          
  thou…    Resul…            Acqui…            to the            Septe…         
                             of                Acqui…            30,            
                             Avadel            of                2025           
                             (1)               Avadel                           
  Cost                                                                          
  of                                                                            
  goods    $       253,9…    $       72,413    $       181,4…    $       150,…  
  manu…                                                                         
  and                                                                           
  sold                                                                          
  Rese…                                                                         
  and      $       337,3…    $        8,314    $       329,0…    $       230,…  
  deve…                                                                         
  Sell…                                                                         
  gene…    $       690,7…    $       57,602    $       633,1…    $       514,…  
  and                                                                           
  admi…                                                                         
  (1)                                                                           
  Incl…                                                                         
  $20,…                                                                         
  of                                                                            
  shar…                                                                         
  comp…                                                                         
  expe…                                                                         
  rela…                                                                         
  to                                                                            
  the                                                                           
  acce…                                                                         
  of                                                                            
  vest…                                                                         
  of                                                                            
  equi…                                                                         
  awar…                                                                         
  for                                                                           
  Avad…                                                                         
  empl…                                                                         
  which                                                                         
  vest…                                                                         
  in                                                                            
  full                                                                          
  upon                                                                          
  the                                                                           
  clos…                                                                         
  of                                                                            
  the                                                                           
  tran…                                                                         
                                                                                
                                       8                                        

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ALKS/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.